Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.

Serum proteomics provides a useful tool to identify potential biomarkers associated with cancer progression. In the present study, a two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS) on a linear ion trap was utilized to identify and compare serum proteins from breast cancer patients. Three groups of 21 human sera, 7 from patients with lymph node-negative invasive ductal carcinoma (IDCB), 7 from patients with lymph node-positive IDCB, and 7 controls from patients with benign breast diseases, were analyzed. Through proteomic analysis, a total of 2,078 proteins were identified with at least two unique peptide hits. By quantification with label-free spectral counting, a fruitful list of serum proteins with significant differences in abundance accompanying the progression of breast cancer was found. Through hierarchical cluster analysis based on the differently expressed proteins in selection, we found that different groups of sera could be distinguished. Among the selected proteins, tenascin-XB (TNXB) was further validated by the ELISA method in 131 serum samples as a promising biomarker for early metastasis of breast cancer. These experiments revealed the valuable potential of label-free quantitative 2D-LC-MS/MS for identification of novel biomarkers for disease progression.

[1]  S. Hanash,et al.  Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. , 2008, Journal of proteome research.

[2]  J. Bristow,et al.  Tenascin–X deficiency is associated with Ehlers–Danlos syndrome , 1997, Nature Genetics.

[3]  I. Gromova,et al.  A single lysis solution for the analysis of tissue samples by different proteomic technologies , 2008, Molecular oncology.

[4]  T. Ikemura,et al.  Structural analysis of mouse tenascin-X: evolutionary aspects of reduplication of FNIII repeats in the tenascin gene family. , 1998, Gene.

[5]  F. Bertucci,et al.  Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy , 2006, Oncogene.

[6]  Nam-Soon Kim,et al.  Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. , 2006, International journal of oncology.

[7]  J. Yates,et al.  Shotgun Proteomics and Biomarker Discovery , 2002, Disease markers.

[8]  C. Huck,et al.  Biomarker discovery in breast cancer serum using 2‐D differential gel electrophoresis/ MALDI‐TOF/TOF and data validation by routine clinical assays , 2006, Electrophoresis.

[9]  H. Ariga,et al.  Tumour invasion and metastasis are promoted in mice deficient in tenascin‐X , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[10]  J. V. Van Eyk,et al.  Effective removal of albumin from serum , 2005, Proteomics.

[11]  S. Gitelman,et al.  Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B , 1993, The Journal of cell biology.

[12]  Emanuel F Petricoin,et al.  Serum proteomics in cancer diagnosis and management. , 2004, Annual review of medicine.

[13]  Manjit Singh,et al.  Isolation, identification and quantification of differentially expressed proteins from cancerous and normal breast tissues , 2008, Annals of clinical biochemistry.

[14]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Goodison,et al.  Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. , 2007, Journal of proteome research.

[16]  F. Lumachi,et al.  Serum tumor markers in patients with breast cancer , 2004, Expert review of anticancer therapy.

[17]  Graham B. I. Scott,et al.  HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples , 2005, Proteomics.

[18]  Jinxiang Han,et al.  Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.

[19]  I. Salmon,et al.  Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1 , 2007, Clinical Cancer Research.

[20]  L. Pannell,et al.  Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. , 2007, Journal of proteome research.

[21]  J. Catanese,et al.  Isolation from opossum serum of a metalloproteinase inhibitor homologous to human alpha 1B-glycoprotein. , 1992, Biochemistry.

[22]  Shinzaburo Noguchi,et al.  mRNA expression level of estrogen‐inducible gene, α1‐antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers , 2004, Cancer science.

[23]  E. Diamandis,et al.  Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.

[24]  S. Shea,et al.  Screening mammography under age 50. , 1999, JAMA.

[25]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[26]  Ken-ichi Matsumoto,et al.  Differential expression of tenascin-C and tenascin-X in human astrocytomas , 1997, Acta Neuropathologica.

[27]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[28]  Timothy D Veenstra,et al.  Serum and plasma proteomics. , 2007, Chemical reviews.

[29]  M. Fukunaga.  Gastric carcinoma resembling pancreatic mixed acinar-endocrine carcinoma. , 2002, Human pathology.

[30]  K. Horwitz,et al.  Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases , 2007, Clinical & Experimental Metastasis.

[31]  C. Shriver,et al.  Label-free Semiquantitative Peptide Feature Profiling of Human Breast Cancer and Breast Disease Sera via Two-dimensional Liquid Chromatography-Mass Spectrometry*S , 2006, Molecular & Cellular Proteomics.

[32]  E. Perez,et al.  Advances in screening, diagnosis, and treatment of breast cancer. , 2004, Mayo Clinic proceedings.

[33]  Junliang Pan,et al.  Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology , 2008, Lung.

[34]  Helen C. Cowley,et al.  Improving the accuracy of mammography: volume and outcome relationships. , 2002, Journal of the National Cancer Institute.

[35]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[36]  P. Meleady,et al.  Proteomic approaches for serum biomarker discovery in cancer. , 2007, Anticancer research.

[37]  Stephen Russell,et al.  High‐throughput proteomic analysis of human infiltrating ductal carcinoma of the breast , 2003, Proteomics.

[38]  W. Hancock,et al.  Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. , 2006, Clinical chemistry.

[39]  B. Spengler,et al.  Identification of leptomeningeal metastasis‐related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI‐TOF, MALDI‐FTICR and nanoLC‐FTICR MS , 2007, Proteomics.

[40]  M. Higashiyama,et al.  Alpha‐1‐antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression , 1995, Cancer.

[41]  T. M. Thomas,et al.  Depletion of the highly abundant protein albumin from human plasma using the Gradiflow , 2003, Proteomics.

[42]  J L Kelsey,et al.  Breast cancer epidemiology. , 1988, Cancer research.

[43]  E. B. Butler,et al.  Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers , 2003, Proteomics.

[44]  L. Alldridge,et al.  Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. , 2008, Journal of proteome research.

[45]  K. Aoki,et al.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma. , 2008, Journal of proteome research.